Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Show more
700 Quince Orchard Road, Gaithersburg, MD, 20878, United States
Start AI Chat
Market Cap
1.521B
52 Wk Range
$5.01 - $10.64
Previous Close
$9.36
Open
$9.35
Volume
2,915,683
Day Range
$9.31 - $9.77
Enterprise Value
1.167B
Cash
762.9M
Avg Qtr Burn
N/A
Insider Ownership
8.79%
Institutional Own.
69.67%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Approved Update | ||
Nuvaxovid (NVX-CoV2705) Details COVID-19 | Approved Update | |
Approved Update | ||
Nuvaxovid (NVX-CoV2373) Details COVID-19 | Approved Update | |
Matrix-M Details Malaria | Phase 3 Update | |
COVID-Influenza combination (CIC) vaccine Details Influenza, COVID-19 | Phase 3 Update | |
NanoFlu vaccine Details Influenza | Phase 2 Update | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued |
